Learn
Delve into dermatology diseases with new approaches from conventional to complementary care.
Topics
Explore a broad spectrum of dermatological conditions and topics to enhance your practice.
Training Programs
Expert led instruction for every level of patient care.
Hover over a program to view enrolled content.
Conferences
Gain practical insights and meet new colleagues.
Hover over a conference to view recordings.
Join Us
The largest integrative dermatology community.
This session will serve as a global discussion of emerging IL-17/23 inhibiting biologics and JAK and TEC inhibitors and how they would be utilized in clinical practice. The discussion will include evidence around safety when utilizing JAK/TEC inhibitors and will draw from the existing literature.
Learning Objectives
After completing this activity, participants will be able to:
- Discuss how clinicians can evaluate the efficacy of JAK/TEC inhibition in the context of other existing therapies for treating chronic systemic inflammatory disease
- Review the safety profile of JAK/TEC inhibitors and discuss the benefit:risk profile for their use
Faculty
Dr. Hawkes is a board-certified dermatologist in the greater Sacramento area. He completed his medical school and residency at the University of Utah. During medical school, he completed a fellowship in translational immunology in the NIH-HHMI Research Scholars Program. He also received a Master’s Degree in Clinical Investigation from Rockefeller University, where he was Chief Clinical Scholar and Principal and sub-Investigator on multiple human research protocols in the Laboratory for Investigative Dermatology. He has held academic appointments in the Departments of Dermatology at the University of Utah, University of California-Davis, Icahn School of Medicine at Mount Sinai.
Dr. Hawkes is a current Councilor in the International Psoriasis Council and serves on the NPF Medical Board and Scientific Advisory Committee. He also serves as the official delegate of the AAD as a member of the international guidelines and workgroup committee for urticaria. His research has been funded by the NIH, NSF, NPF, and Dermatology Foundation, and he is the recipient of several teaching awards including NPF Outstanding Educator in Psoriatic Disease and Exceptional Teacher of the Year in the Department of Dermatology at Mount Sinai. His primary clinical and research interests include novel immune therapies for inflammatory conditions like psoriasis, atopic dermatitis, HS, alopecia areata, vitiligo, and urticaria.
Editors
Dr. Hadar Lev-Tov is a board-certified dermatologist with extensive research experience. Throughout his training and in daily practice, he has always believed that the key to achieving health for his patients is grounded in his ability to truly connect to their experiences and perceptions of health and well-being. Maimonides, one of the greatest philosophers of all time realized that human knowledge, often represented as "science," is limited. As a physician, he feels he would be a fool to believe all is known. Maimonides said, "The physician should not treat the disease but the patient who is suffering from it." LearnSkin is his journey to a better understanding of his patients.
Related Courses
Hidradenitis Suppurativa
The Approach to Hidradenitis Suppurativa in Those with Skin of Color
Hidradenitis Suppurativa
Shared Decision Making in Hidradenitis Suppurativa: An Integrative Approach
Hidradenitis Suppurativa
Expert Panel on Hidradenitis Suppurativa
Hidradenitis Suppurativa
Understanding Aspects of Shared Decision Making in a Patient with Hidradenitis Suppurativa
